Lipid-Lowering Agents - Switzerland

Switzerland

Highlights

In Switzerland, the revenue in the market of Lipid-Lowering Agents market is forecasted to achieve CHF US$60.93m by 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of -0.06%, leading to a market volume of CHF US$60.73m by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching US$4.46bn in 2024.
In Switzerland, the demand for Lipid-Lowering Agents is steadily increasing due to the country's high prevalence of cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Lipid-Lowering Agents market in Switzerland has been experiencing steady growth in recent years.

Customer preferences: Swiss customers tend to be health-conscious and place a high value on preventative healthcare. As a result, there is a high demand for lipid-lowering agents in the country. Patients are increasingly seeking out medications that can help them manage their cholesterol levels and reduce their risk of heart disease.

Trends in the market: One trend that has been driving the growth of the lipid-lowering agents market in Switzerland is the increasing use of combination therapies. Many patients are now taking multiple medications to manage their cholesterol levels, and pharmaceutical companies are responding by developing combination therapies that can simplify treatment regimens and improve patient outcomes.Another trend that is shaping the market is the growing use of generic drugs. As patents on many popular lipid-lowering agents have expired, generic versions of these drugs have become available at lower prices. This has made it easier for patients to access these medications and has put pressure on pharmaceutical companies to develop new, innovative therapies to remain competitive.

Local special circumstances: One unique aspect of the Swiss market is the country's strong regulatory environment. The Swiss Agency for Therapeutic Products (Swissmedic) has strict requirements for drug approval, which can make it challenging for pharmaceutical companies to bring new products to market. However, this also ensures that only safe and effective medications are available to Swiss patients.

Underlying macroeconomic factors: Switzerland has a strong economy and a high standard of living, which has led to a relatively healthy population. However, the country's aging population and high rates of obesity and diabetes are contributing to an increased demand for lipid-lowering agents. Additionally, the Swiss healthcare system is highly decentralized, which can make it difficult for pharmaceutical companies to navigate the complex landscape of different insurance providers and hospital networks.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.